163 related articles for article (PubMed ID: 30568255)
21. A stimulatory thyrotropin receptor antibody enhances hyaluronic acid synthesis in graves' orbital fibroblasts: inhibition by an IGF-I receptor blocking antibody.
Kumar S; Iyer S; Bauer H; Coenen M; Bahn RS
J Clin Endocrinol Metab; 2012 May; 97(5):1681-7. PubMed ID: 22399503
[TBL] [Abstract][Full Text] [Related]
22. Orbital fibrosis in a mouse model of Graves' disease induced by genetic immunization of thyrotropin receptor cDNA.
Zhao SX; Tsui S; Cheung A; Douglas RS; Smith TJ; Banga JP
J Endocrinol; 2011 Sep; 210(3):369-77. PubMed ID: 21715431
[TBL] [Abstract][Full Text] [Related]
23. Putative protective role of autoantibodies against the insulin-like growth factor-1 receptor in Graves' Disease: results of a pilot study.
Lanzolla G; Ricci D; Nicolì F; Sabini E; Sframeli A; Brancatella A; Mantuano M; Dottore GR; Bucci I; Figus M; Nardi M; Latrofa F; Marcocci C; Marinò M
J Endocrinol Invest; 2020 Dec; 43(12):1759-1768. PubMed ID: 32583374
[TBL] [Abstract][Full Text] [Related]
24. Thyrotropin receptor expression in Graves' orbital adipose/connective tissues: potential autoantigen in Graves' ophthalmopathy.
Bahn RS; Dutton CM; Natt N; Joba W; Spitzweg C; Heufelder AE
J Clin Endocrinol Metab; 1998 Mar; 83(3):998-1002. PubMed ID: 9506762
[TBL] [Abstract][Full Text] [Related]
25. Thyrotropin receptor expression in orbital adipose/connective tissues from patients with thyroid-associated ophthalmopathy.
Bahn RS
Thyroid; 2002 Mar; 12(3):193-5. PubMed ID: 11952038
[TBL] [Abstract][Full Text] [Related]
26. TSHR as a therapeutic target in Graves' disease.
Smith TJ
Expert Opin Ther Targets; 2017 Apr; 21(4):427-432. PubMed ID: 28127991
[TBL] [Abstract][Full Text] [Related]
27. Immune reconstitution after alemtuzumab therapy for multiple sclerosis triggering Graves' orbitopathy: a case series.
Roos JCP; Moran C; Chatterjee VK; Jones J; Coles A; Murthy R
Eye (Lond); 2019 Feb; 33(2):223-229. PubMed ID: 30498266
[TBL] [Abstract][Full Text] [Related]
28. Cutting edge: retrobulbar inflammation, adipogenesis, and acute orbital congestion in a preclinical female mouse model of Graves' orbitopathy induced by thyrotropin receptor plasmid-in vivo electroporation.
Moshkelgosha S; So PW; Deasy N; Diaz-Cano S; Banga JP
Endocrinology; 2013 Sep; 154(9):3008-15. PubMed ID: 23900776
[TBL] [Abstract][Full Text] [Related]
29. Immunopathogenesis of Graves' ophthalmopathy: the role of the TSH receptor.
Iyer S; Bahn R
Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):281-9. PubMed ID: 22632365
[TBL] [Abstract][Full Text] [Related]
30. Immune mechanisms in thyroid eye disease.
Lehmann GM; Feldon SE; Smith TJ; Phipps RP
Thyroid; 2008 Sep; 18(9):959-65. PubMed ID: 18752427
[TBL] [Abstract][Full Text] [Related]
31. A stimulatory thyrotropin receptor antibody (M22) and thyrotropin increase interleukin-6 expression and secretion in Graves' orbital preadipocyte fibroblasts.
Kumar S; Schiefer R; Coenen MJ; Bahn RS
Thyroid; 2010 Jan; 20(1):59-65. PubMed ID: 20017620
[TBL] [Abstract][Full Text] [Related]
32. Correlation between serum anti-TSH receptor autoantibodies (TRAbs) and the clinical feature of Graves' orbitopathy.
Nicolì F; Lanzolla G; Mantuano M; Ionni I; Mazzi B; Leo M; Sframeli A; Posarelli C; Maglionico MN; Figus M; Nardi M; Marcocci C; Marinò M
J Endocrinol Invest; 2021 Mar; 44(3):581-585. PubMed ID: 32648002
[TBL] [Abstract][Full Text] [Related]
33. Application of new therapies in Graves' disease and thyroid-associated ophthalmopathy: animal models and translation to human clinical trials.
Banga JP; Nielsen CH; Gilbert JA; El Fassi D; Hegedus L
Thyroid; 2008 Sep; 18(9):973-81. PubMed ID: 18752425
[TBL] [Abstract][Full Text] [Related]
34. Blocking the Thyrotropin Receptor with K1-70 in a Patient with Follicular Thyroid Cancer, Graves' Disease, and Graves' Ophthalmopathy.
Ryder M; Wentworth M; Algeciras-Schimnich A; Morris JC; Garrity J; Sanders J; Young S; Sanders P; Furmaniak J; Rees Smith B
Thyroid; 2021 Oct; 31(10):1597-1602. PubMed ID: 34114495
[No Abstract] [Full Text] [Related]
35. [The role of adipose tissue in the pathogenesis and clinical manifestation of Graves' orbitopathy].
Janusz P; Pawlak-Adamska E; Kochanowska IE; Daroszewski J
Postepy Hig Med Dosw (Online); 2013 Dec; 67():1173-81. PubMed ID: 24379258
[TBL] [Abstract][Full Text] [Related]
36. [Graves' ophthalmopathy].
Hiromatsu Y
Nihon Rinsho; 2006 May; Suppl 1():307-10. PubMed ID: 16776151
[No Abstract] [Full Text] [Related]
37. Th1/Th2 cytokines in patients with Graves' disease with or without ophthalmopathy.
Esfahanian F; Naimi E; Doroodgar F; Jadali Z
Iran J Allergy Asthma Immunol; 2013 May; 12(2):168-75. PubMed ID: 23754356
[TBL] [Abstract][Full Text] [Related]
38. Association between thyroid-stimulating immunoglobulin levels and ocular findings in pediatric patients with Graves disease.
Acuna OM; Athannassaki I; Paysse EA
Trans Am Ophthalmol Soc; 2007; 105():146-50; discussion 150-1. PubMed ID: 18427604
[TBL] [Abstract][Full Text] [Related]
39. [Endocrine orbitopathy and significance of autoantibodies against 1D protein].
Hrdá P; Sterzl I; Vána S; Novák Z; Matucha P; Kromminga A
Cas Lek Cesk; 2007; 146(3):273-7. PubMed ID: 17419313
[TBL] [Abstract][Full Text] [Related]
40. Pathological Findings of the Thyroid Tissue in a Patient with Euthyroid Graves' Disease.
Suzuki N; Yoshihara A; Yoshimura Noh J; Kozaki A; Inoue T; Sugino K; Ito K
Intern Med; 2015; 54(22):2881-4. PubMed ID: 26568003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
